Home・Elenco Azioni・Viking Therapeutics Inc

Viking Therapeutics Inc

Chiusa

SettoreSettore sanitario

33.86 1.77

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

33.85

Metriche Chiave
By Trading Economics
Entrata	30M -128M
EPS	-1.1
Dipendenti	65
EBITDA	30M -128M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+167.62% upside

Dividendi
By Acuity
Utili prossimi	21 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-126M 3.9B
Apertura precedente	32.09
Chiusura precedente	33.86

Notizie sul Sentiment di mercato

By Acuity

50%

156 / 340 Classifica in Healthcare

Viking Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 ago 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 ago 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 ago 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 ago 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 ago 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 ago 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 ago 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 ago 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 ago 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 ago 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 lug 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 lug 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 lug 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 lug 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 lug 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 lug 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 lug 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 lug 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 lug 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Confronto tra pari

Modifica del prezzo

Viking Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

167.62% in crescita

Previsioni per 12 mesi

Media 90 USD 167.62%

Alto 114 USD

Basso 65 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viking Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a Viking Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

156 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.